Streptococcus pneumoniae é o principal causador da pneumonia bacteriana. As vacinas atualmente disponíveis contêm polissacarídeo capsular conjugado ou não com proteínas carreadoras. No entanto, elas apresentam elevado custo ou proteção reduzida nos grupos de risco (crianças abaixo de 5 anos de idade e idosos). Proteínas de superfície de S. pneumoniae, como a PsaA e PspA, são consideradas fortes candidatas vacinais. Com o objetivo de se desenvolver uma vacina de ampla cobertura e baixo custo contra pneumococos, os genes psaA e pspA foram clonados em vetores de expressão em E. coli, pAE e pET e as proteínas expressas foram purificadas por cromatografias de afinidade e de troca aniônica. O rendimento de proteína recombinante obtido com a construção baseada em pET foi 3 vezes maior que o obtido com pAE. Condições de cultivo foram estabelecidas utilizando meio definido com indução por IPTG e/ou por lactose. As cepas recombinantes estão adequadas para serem usadas em estudos para escalonamento da produção em biorreatores. / Streptococcus pneumoniae is the main causative agent of bacterial pneumonia. The current vaccines available contain capsular polysaccharide conjugated or not with carrier proteins. However these are either too expensive or do not protect the high-risk groups. Surface proteins of S. pneumoniae, such as PsaA and PspA, are considered strong vaccine candidates. With the aim of developing a broad-coverage and low-cost vaccine against pneumococcus, the psaA and pspA genes were cloned in E. coli expression vectors, pAE and pET and the expressed proteins were purified through affinity and anion exchange chromatography. The yield of the recombinant protein obtained with the construction based in pET was 3-fold higher than that obtained with pAE. Culture conditions were established using defined media with IPTG and/or lactose induction. The recombinant strains are now ready to undergo studies for scale-up of production in bioreactors.

Background The inducible Cre-lox system is a valuable tool to study gene function in a spatial and time restricted fashion in mouse models. This strategy relies on the limited background activity of the modified Cre recombinase (CreER) in the absence of its inducer, the competitive estrogen receptor ligand, tamoxifen. The RIP-CreER mouse (Tg (Ins2-cre/Esr1) 1Dam) is among the few available β-cell specific CreER mouse lines and thus it has been often used to manipulate gene expression in the insulin-producing cells of the endocrine pancreas. Principal Findings Here, we report the detection of tamoxifen-independent Cre activity as early as 2 months of age in RIP-CreER mice crossed with three distinct reporter strains. Significance Evidence of Cre-mediated recombination of floxed alleles even in the absence of tamoxifen administration should warrant cautious use of this mouse for the study of pancreatic β-cells.

Liposomes are versatile biocompatible and biodegradable carriers for a variety of medical applications. As the first nanoparticles, they have been approved for pharmaceutical use so far, and many liposome-based preparations are in clinical trials. Classical methods of liposome preparation represent potential limitations in technology transfer from laboratory to industrial scale. New, microfluidic techniques overcome these limitations and offer new possibilities for controlled, continuous preparation of liposomal particles in a laboratory and industrial scale. An important element in the development of new nanoparticle systems is their complex characterization and purification. In addition to the established chromatographic techniques, the Field flow fractionation technique, in particular the Asymmetrical flow Field-flow fractionation, is described. This relatively new technique in conjunction with the MALS/DLS/DAD-UV/dRI online detectors enables the purification and characterization of complex samples. The main advantage of this technique lies in the possibility of separation under native conditions, which plays an important role in the separation of biopolymers in particular. Separation in the “empty” channel then eliminates sample degradation due to unwanted interactions at the stationary phase-sample interface. The theoretical part of this thesis describes the possibilities of preparation, modification, and characterization of liposomal nanoparticles. For this purpose, optical methods based on dynamic light scattering, multi-angle dynamic light scattering and nanoparticle tracking analysis techniques are described, as well as a non-optical method using "particle by the particle" analysis, tunable resistive pulse sensing method. A separate chapter of the theoretical part is dedicated to the technique Asymmetrical flow Field-flow fractionation in connection with the above-mentioned detectors. Important results associated with this work are summarized in the attached scientific paper, together with the result summaries and the author's contributions.

Herz-Kreislauf-Erkrankungen sind nach wie vor die häufigste Todesursache. Vor allem Bluthochdruck ist in diesem Zusammenhang ein wichtiger Risikofaktor für die Entstehung von koronaren Herzerkrankungen, Myokardinfarkten, Herzinsuffizienz und Schlaganfall. Zur Behandlung der Hypertonie werden unterschiedliche Pharmaka eingesetzt, hauptsächlich Substanzen, die das Renin-Angiotensin-Aldosteron-System (RAAS) hemmen. Dazu gehören synthetische Inhibitoren des angiotensin-converting enzyme (ACE). Für präventive Zwecke können diese ACE-Inhibitoren auf Grund mehrerer Nebenwirkungen nicht eingesetzt werden. Interessant für eine präventive Anwendung sind natürliche ACE-hemmende Peptide, welche in der Sequenz unterschiedlicher Lebensmittelproteine vorliegen und durch enzymatische Hydrolyse freigesetzt werden. Ein besonders potenter ACE-Hemmer ist das Dipeptid Isoleucin-Tryptophan (IW) und damit ein interessanter Kandidat für den Einsatz in einem funktionellen Lebensmittel. Um dies jedoch realisieren zu können, muss IW in einer ausreichenden Menge produziert werden. Durch die enzymatische Hydrolyse ist dies aktuell nicht möglich, da die Peptidsequenz IW sehr selten in Proteinen vorhanden ist. Aus diesem Grund war es Ziel der vorliegenden Arbeit eine innovative biotechnologische Methode zu etablieren, um das ACE-hemmende Dipeptid IW in höheren Mengen und vor allem lebensmittelkonform zu produzieren. Die Produktion des ACE-hemmenden Peptids wurde biotechnologisch mittels rekombinanter DNA-Technologie realisiert. Hierfür wurde eine repetitive IW-Sequenz entworfen (264 bp), welche für ein 10 kDa großes Protein codierte. Dieses IW-Konstrukt enthielt in der Sequenz 16-mal IW. Mit Hilfe von Escherichia coli (E. coli) wurde ein 52 kDa großes Fusionsprotein überexprimiert. Als Fusionstag diente das Maltose Binding Protein (MBP). Dieses rekombinante Fusionsprotein (MBP-IW) lag nach einer Kombination von zwei verschiedenen chromatographischen Verfahren gereinigt vor. Mit dieser Methode war es möglich, 0,52 mg lösliches MBP-IW pro 1 g E. coli Feuchtmasse zu produzieren. MBP-IW wurde enzymatisch mit dem Enzym α-Chymotrypsin hydrolisiert und das Dipeptid IW anschließend chromatographisch isoliert. Nach der Hydrolyse und Isolation lag die Ausbeute des rekombinant produzierten IW (rIW) mit einer Reinheit von ≥ 96 % bei 14 µg. Somit konnten 28 % des möglichen Anteils an rIW vom sauberen MBP-IW gewonnen werden. Die Identifikation von IW erfolgte mit drei unterschiedlichen Methoden, der reversed phase-high performance liquid chromatography-UV-Detektion, der liquid chromatography-electrospray ionisation-tandem mass spectrometry und durch eine N-terminale Derivatisierung des Peptids. Mit diesen Methoden wurde bestätigt, dass es sich bei dem produzierten Peptid um IW handelte. Das rIW wurde im Vergleich zum chemisch produzierten kommerziell erwerblichen L-IW (cIW) und chemisch produzierten kommerziell erwerblichen D-IW (cDIW) auf sein ACE-hemmendes Potential getestet. Um der komplexen und heterogenen Verteilung der ACE-Aktivität im menschlichen Organismus gerecht zu werden, wurde das ACE-hemmende Potential der Dipeptide an verschiedenen ACE-Quellen untersucht. Neben dem nicht-humanen ACE-System (ACE aus der Kaninchenlunge) wurde auch humanes lösliches ACE (aus humanem Plasma) sowie humanes membrangebundenes ACE (aus Human umbilical vein endothelial cells, HUVECs) verwendet. Bei allen getesteten ACE-Systemen zeigte sich kein ACE-hemmendes Potential durch cDIW. Beim Vergleich von rIW mit cIW in Bezug auf deren ACE-hemmendes Potential wurden IC50-Werte von 1,72 ± 0,12 bis 23,30 ± 3,68 µM, abhängig vom getesteten ACE-System, bestimmt. Für alle verwendeten ACE-Quellen konnte gezeigt werden, dass beide unterschiedlich produzierten Dipeptide gleich effektiv waren. Ein weiteres Ziel der Arbeit bestand darin neben einem Peptidmix aus Molkenprotein mit hohem Anteil an IW, noch zwei weitere Peptidmixe pflanzlichen Proteinursprungs hinsichtlich des ACE-hemmenden Potentials zu untersuchen. Auf Grundlage der identifizierten tryptophan- und tyrosinhaltigen Dipeptide in den Hydrolysaten des Molken-, Soja- und Reisproteins wurden drei Peptidmixe hergestellt. Auch hier wurde wieder die Wirkung auf mehrere ACE-Quellen ermittelt. Neben den oben genannten, wurde hier zusätzlich der Einfluss auf membrangebundenes ACE der Rattenaorta untersucht. In allen getesteten ACE-Systemen zeigte der Peptidmix Molke ein signifikant höheres ACE-hemmendes Potential als die Peptidmixe von Soja und Reis. Der Peptidmix Soja war von den getesteten hydrolisierten Pflanzenproteinen der potenteste ACE-Inhibitor. Die IC50-Werte der Peptidmixe lagen, je nach getestetem ACE-System, zwischen 16,60 ± 2,59 und 282,04 ± 18,51 mg/l. Der starke ACE-hemmende Effekt vom Peptidmix Molke wurde mit der hohen Konzentration an IW assoziiert (bis zu 10-fach höher verglichen mit den anderen beiden Peptidmixen). Dies legt nahe, dass das Dipeptid IW hauptverantwortlich für das ACE-hemmende Potential in den getesteten Peptidmixen ist, was nochmals das große Potential des Dipeptids verdeutlicht. Im Rahmen dieser Arbeit konnte gezeigt werden, dass IW aus Molkenprotein im Vergleich mit den bioaktiven Peptidquellen der Proteine aus Soja und Reis, die stärkste ACE-Hemmung aufweist. Des Weiteren ist es erstmals gelungen, das ACE-hemmende Dipeptid IW in hoher Reinheit biotechnologisch mit Hilfe von rekombinanten Proteinen herzustellen. Um den Einsatz als funktionelles Lebensmittel realisieren zu können, müsste im Weiteren die biotechnologische Herstellung von IW optimiert werden, um eine höhere Ausbeute zu generieren. Nach dieser Optimierung könnte in einem Scale-up Verfahren so viel an IW gewonnen werden, dass es industriell einsetzbar wäre. Die ACE-hemmende Wirkung des biotechnologisch hergestellten IWs wurde in dieser Arbeit bestätigt, sodass es in einem innovativen funktionellen Lebensmittel für die tägliche Ernährung eingesetzt werden könnte. Perspektivisch eröffnet sich damit die Möglichkeit IW präventiv zu nutzen, um die Entwicklung von Bluthochdruck und deren Folgeschädigungen zu verzögern oder zu minimieren. / Cardiovascular diseases are still the leading cause of death. Especially hypertension is an important risk factor for the development of coronary heart disease, myocardial infarction, heart failure and stroke. To treat hypertension different drugs are clinically used. This are mainly substances, which inhibit the renin-angiotensin-aldosterone-system (RAAS), such as synthetic inhibitors of angiotensin-converting enzyme (ACE). However these ACE-inhibitors cannot be used for preventive purposes because of several side effects. Therefore natural ACE-inhibitory peptides, which are mostly encrypted in food proteins and released by enzymatic hydrolysis, are of main interest for preventive applications. The dipeptide isoleucine-tryptophan (IW) is a potent ACE-inhibitor and thus an interesting ingredient in functional foods. However, to realize this, IW must be produced in sufficient amounts. This is not possible with the current enzymatic hydrolysis, because the peptide sequence of IW is very rarely present in proteins. For that reason, the aim of the present thesis was to establish an innovative biotechnological method to produce the ACE-inhibitory dipeptide IW in an enlarged amount and especially considering the food-safety. The production of the ACE-inhibitory peptide was realized biotechnologically via recombinant DNA technology. For this, a repetitive IW-sequence (264 bp) was designed, which encoded a 10 kDa protein. In this IW-construct IW was sequenced 16 times. Using Escherichia coli (E. coli) a fusion protein with a size of 52 kDa was overexpressed. The maltose binding protein (MBP) served as fusion tag. This recombinant fusion protein (MBP-IW) was purified by a combination of two different chromatographic methods. It has become possible to produce 0.52 mg of soluble MBP-IW per 1 g wet weight of E. coli. MBP-IW was enzymatically hydrolysed with the enzyme α-chymotrypsin and the dipeptide IW was subsequently isolated by chromatography. After hydrolysis and isolation, the yield of the recombinant produced IW (rIW) with a purity of ≥ 96 % was 14 μg. Thus, 28 % from the possible content of rIW was obtained from the clean MBP-IW. IW was identified by three different methods: reversed phase-high performance liquid chromatography with UV-detection, liquid chromatography-electrospray ionisation-tandem mass spectrometry and N-terminal derivatization of the peptide. These methods confirmed the produced peptide as IW. The ACE-inhibitory potential of rIW was analysed and compared to that of the chemically produced commercially available L-IW (cIW) and of the chemically produced commercially available D-IW (cDIW). To address the complex and heterogeneous distribution of ACE-activity in the human organism, the ACE-inhibitory potential of the dipeptides was investigated in different ACE-sources. Additionally to non-human ACE (from rabbit lung) also human soluble ACE (from human plasma) and human membrane-bound ACE (from human umbilical vein endothelial cells, HUVECs) were used. In all tested ACE-systems cDIW did not show any ACE-inhibitory effect. IC50 values of rIW and cIW ranged from 1.72 ± 0.12 to 23.30 ± 3.68 μM, depending on the investigated ACE-system. In all sources of ACE an equal inhibitory potency of both differently produced dipeptides were determined. The second aim of the thesis was to investigate the ACE-inhibitory effect of two peptide mixes of plant proteins beside the peptide mix of whey protein, containing a high concentration of IW. Based on the identified tryptophan- and tyrosine-containing dipeptides in the hydrolysates of the whey-, soy- and rice-protein, three peptide mixes were prepared. Also here the effect on different ACE-sources was determined. Additionally to the named above, membrane-bound ACE from rat aorta was investigated. In all analysed ACE-systems, the peptide mix of whey showed a significantly higher ACE-inhibitory potential than the peptide mixes of soy and rice. The peptide mix soy was the most potent ACE-inhibitor tested among the hydrolysed plant proteins. The IC50-values of the peptide mixes were between 16.60 ± 2.59 and 282.04 ± 18.51 mg/l, depending on the used ACE-system. The strong ACE-inhibitory effect of the whey peptide mix was associated with the high concentration of IW (10 times higher compared to the other peptide mixes). This indicates that the dipeptide IW is mainly responsible for the ACE-inhibitory potential in the investigated peptide mixes, which demonstrate again the great potential of this dipeptide. It was shown in the present study that IW from whey protein had the strongest ACE-inhibition compared to the bioactive peptides of proteins from soy and rice. Furthermore, for the first time it was possible to produce the ACE-inhibitory dipeptide IW in high purity biotechnologically using recombinant proteins. To use IW as an ingredient in functional foods, the biotechnological production of IW needs to be optimized to receive higher yields. After this optimization, it would be conceivable to increase the production of IW in a scale-up process for industrial application. The ACE-inhibitory effect of the biotechnologically produced IW was confirmed in the present study, thus it could be used in an innovative functional food for daily nutrition. Prospectively, this increases the possibility of using IW preventively in order to delay or minimize the development of hypertension and the consequentially diseases.

The recombinant product is secreted to the periplasm in many processes where E. coli is used as host. One drawback with secretion is the undesired leakage of the periplasmic products to the medium. The aim of this work was to find strategies to influence the periplasmic retention of recombinant products. We have focused on the role of the specific growth rate, a parameter that is usually controlled in industrial bioprocesses. The hypothesis was that the stability of the outer membrane in E. coli is gained from a certain combination of specific phospholipids and fatty acids on one side and the amount and specificity of the outer membrane proteins on the other side, and that the specific growth rate influences this structure and therefore can be used to control the periplasmic retention. We found that is possible to control the periplasmic retention by the growth rate. The leakage of the product increased as the growth rate increased. It was however also found that a higher growth rate resulted in increased productivity. This resulted in equal amounts of product inside the cells regardless of growth rate. We also showed that the growth rate influenced the outer membrane composition with respect to OmpF and LamB while OmpA was largely unaffected. The total amount of outer membrane proteins decreased as the growth rate increased. There were further reductions in outer membrane protein accumulation when the recombinant product was secreted to the periplasm. The lowered amount of outer membrane proteins may have contributed to the reduced ability for the cell to retain the product in the periplasm. The traditional way to control the growth rate is through a feed of substrate in a fed-batch process. In this work we used strains with a set of mutations in the phosphotransferase system (PTS) with a reduced uptake rate of glucose to investigate if these strains could be used for growth rate control in batch cultivations without the use of fed-batch control equipment. The hypothesis was that the lowering of the growth rate on cell level would result in the establishment of fed-batch similar conditions. This study showed that it is possible to control the growth rate in batch cultivations by using mutant strains with a decreased level of substrate uptake rate. The mutants also produced equivalent amounts of acetic acid as the wild type did in fed-batch cultivation with the same growth rate. The oxygen consumption rates were also comparable. A higher cell density was reached with one of the mutants than with the wild type in batch cultivations. It is possible to control the growth rate by the use of the mutants in small-scale batch cultivations without fed-batch control equipment. / QC 20101108

by Wai Ching Man. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2005. / Includes bibliographical references (leaves 154-159). / Abstracts in English and Chinese. / Statement --- p.ii / Acknowledgements --- p.iii / Abstract --- p.v / 摘要 --- p.vii / List of Abbreviations --- p.viii / Table of contents --- p.x / List of Tables --- p.xiv / List of Figures --- p.xv / Chapter Chapter 1 --- Introduction --- p.1 / Chapter Chapter 2 --- Literature review --- p.4 / Chapter 2.1 --- Plant lectins --- p.4 / Chapter 2.1.1 --- Introduction --- p.4 / Chapter 2.1.2 --- Definition and subdivision of plant lectins --- p.4 / Chapter 2.2 --- Monocot mannose-binding lectins --- p.6 / Chapter 2.2.1 --- Occurrence and carbohydrate binding specificity --- p.6 / Chapter 2.2.2 --- Molecular structure and amino acid sequence --- p.7 / Chapter 2.2.3 --- "Molecular cloning, biosynthesis and post-translational modification" --- p.10 / Chapter 2.2.4 --- Mannose-binding lectins of Family Liliaceae --- p.11 / Chapter 2.2.4.1 --- Tulipa gesneriana lectins (TGL) --- p.12 / Chapter 2.2.4.2 --- Aloe arborescens lectins (AAL) --- p.13 / Chapter 2.2.4.3 --- Polygonatum multiflorum agglutinin (PMA) and lectin-related protein --- p.14 / Chapter 2.3 --- Polygonatum odoratum lectins (POL) --- p.15 / Chapter 2.3.1 --- Isolation and purification of POL from Yu Chu --- p.15 / Chapter 2.3.2 --- Agglutinating activity and anti-viral activities of POL --- p.17 / Chapter 2.3.3 --- Bacterial expression of POL in Escherichia coli --- p.18 / Chapter 2.4 --- Plant-based production of recombinant proteins --- p.20 / Chapter 2.4.1 --- Advantages of using plants as expression system --- p.20 / Chapter 2.4.2 --- Plant-derived recombinant proteins --- p.22 / Chapter 2.5 --- Expression of heterologous proteins in rice --- p.24 / Chapter 2.5.1 --- The facts of rice --- p.24 / Chapter 2.5.2 --- Rice storage proteins --- p.25 / Chapter 2.5.2 --- Expression of lysine-rich protein (LRP)/glutelin fusion proteinin rice seeds --- p.28 / Chapter 2.5.3 --- Expression of Galanthus nivalis agglutinin in rice --- p.29 / Chapter 2.6 --- Protein trafficking in plants --- p.30 / Chapter 2.6.1 --- Golgi-dependent pathways --- p.30 / Chapter 2.6.2 --- Golgi-independent pathway --- p.32 / Chapter 2.6.3 --- Expression of protein targeting determinants in tobacco plants and suspension cells --- p.33 / Chapter Chapter 3 --- Materials and Methods --- p.35 / Chapter 3.1 --- Introduction --- p.35 / Chapter 3.2 --- Chemcials --- p.35 / Chapter 3.3 --- Bacterial strains --- p.35 / Chapter 3.4 --- Cloning of POL cDNA --- p.36 / Chapter 3.4.1 --- Plant materials --- p.36 / Chapter 3.4.2 --- RNA extraction --- p.36 / Chapter 3.4.3 --- RT-PCR amplification of POL cDNA --- p.36 / Chapter 3.4.4 --- 5'RACE and 3'RACE --- p.38 / Chapter 3.4.5 --- Sequencing of POL cDNA --- p.39 / Chapter 3.5 --- Analysis of POL protein --- p.40 / Chapter 3.5.1 --- Protein extraction and Tricine-SDS PAGE --- p.40 / Chapter 3.5.2 --- Western blot analysis --- p.41 / Chapter 3.6 --- Chimeric gene construction --- p.42 / Chapter 3.6.1 --- Construction of the Cauliflower mosaic virus (CaMV)35S promoter/POL constructs --- p.44 / Chapter 3.6.2 --- Construction of the glutelin-1 promoter/POL constructs --- p.48 / Chapter 3.6.3 --- Sequence fidelity of chimeric genes --- p.55 / Chapter 3.7 --- Expression of transgenes in rice --- p.55 / Chapter 3.7.1 --- Plant materials --- p.55 / Chapter 3.7.2 --- Agrobacterium transformation --- p.55 / Chapter 3.7.3 --- Callus induction --- p.56 / Chapter 3.7.4 --- Agrobacterium culture and rice transformation --- p.56 / Chapter 3.7.5 --- Selection and regeneration of rice callus --- p.56 / Chapter 3.7.6 --- Isolation of genomic DNA --- p.58 / Chapter 3.7.7 --- Southern blot analysis --- p.58 / Chapter 3.7.8 --- Extraction of leaf total RNA --- p.59 / Chapter 3.7.9 --- Extraction of seed total RNA --- p.59 / Chapter 3.7.10 --- Northern blot analysis --- p.60 / Chapter 3.7.11 --- Protein extraction and Tricine SDS-PAGE --- p.60 / Chapter 3.7.12 --- Western blot analysis --- p.61 / Chapter 3.8 --- Cytopathic effect (CPE) reduction assay --- p.61 / Chapter 3.8.1 --- Protein extraction --- p.61 / Chapter 3.8.2 --- CPE reduction assay --- p.62 / Chapter 3.9 --- Confocal immunofluorescence --- p.63 / Chapter 3.9.1 --- Preparation of sections --- p.63 / Chapter 3.9.2 --- Labelling of fluorescence probes --- p.63 / Chapter 3.9.3 --- Image collection --- p.64 / Chapter Chapter 4 --- Results --- p.65 / Chapter 4.1 --- Cloning of POL cDNA from Yu Chu --- p.65 / Chapter 4.1.1 --- RNA extraction and partial POL cDNA amplification --- p.65 / Chapter 4.1.2 --- 5'RACE and 3'RACE --- p.67 / Chapter 4.1.3 --- Sequencing of POL cDNA --- p.68 / Chapter 4.1.4 --- Sequences comparison of POL and Liliaceae lectins --- p.75 / Chapter 4.2 --- Occurence of POL protein in Yu Chu plant --- p.77 / Chapter 4.3 --- Constitutional expression of POL in rice --- p.79 / Chapter 4.3.1 --- Construction of Cauliflower mosaic virus 35S promoter constructs --- p.80 / Chapter 4.3.2 --- Southern blot analysis --- p.82 / Chapter 4.3.3 --- Northern blot analysis --- p.84 / Chapter 4.3.4 --- Western blot analysis --- p.85 / Chapter 4.3.5 --- Western blot analysis of 35S/POL T1 plant --- p.87 / Chapter 4.4 --- Seed-specific expression of POL in rice --- p.88 / Chapter 4.4.1 --- Construction of the glutelin-1 promoter constructs --- p.89 / Chapter 4.4.2 --- Southern blot analysis --- p.92 / Chapter 4.4.3 --- Northern blot analysis --- p.96 / Chapter 4.4.4 --- Western blot analysis --- p.101 / Chapter 4.4.5 --- Western blot analysis of POL-BP-8O and POL-α-TIP T1 transgenic plants --- p.117 / Chapter 4.5 --- Cytopathic effect (CPE) reduction assay --- p.122 / Chapter 4.6 --- Confocal immunofluorescence studies --- p.125 / Chapter Chapter 5 --- Discussion --- p.134 / Chapter 5.1 --- Cloning of POL cDNA --- p.134 / Chapter 5.2 --- Analysis of constitutional expression of POL in rice --- p.136 / Chapter 5.3 --- Analysis of seed-specific expression of POL in rice --- p.138 / Chapter 5.4 --- Localization of POL in POL-BP-8O and POL-α-TIP transgenic rice seeds --- p.146 / Chapter 5.5 --- Cytopathic effect (CPE) reduction assay --- p.148 / Chapter 5.6 --- Future prospects --- p.151 / Chapter Chapter 6 --- Conclusion --- p.153

The generation of recombinant antibodies (Abs) using phage display is a proven method to obtain a large variety of Abs that bind with high affinity to a given antigen. Traditionally, the generation of single-chain Abs depends on the use of recombinant proteins in several stages of the procedure. This can be a problem, especially in the case of cell-surface receptors, because Abs generated and selected against recombinant proteins may not bind the same protein expressed on a cell surface in its native form and because the expression of some receptors as recombinant proteins is problematic. To overcome these difficulties, we developed a strategy to generate single-chain Abs that does not require the use of recombinant protein at any stage of the procedure. In this strategy, stably transfected cells are used for the immunization of mice, measuring Ab responses to immunization, panning the phage library, high-throughput screening of arrayed phage clones, and characterization of recombinant single-chain variable regions. This strategy was used to generate a panel of single-chain Abs specific for the innate immunity receptor Toll-like receptor 2. Once generated, individual single-chain variable regions were subcloned into an expression vector allowing the production of recombinant Abs in insect cells, thus avoiding the contamination of recombinant Abs with microbial products. This cell-based system efficiently generates Abs that bind to native molecules on the cell surface, bypasses the requirement of recombinant protein production, and avoids risks of microbial component contamination. / Dissertation

O Antígeno 1 de Membrana Apical (AMA-1) de Plasmodium sp tem sido sugerido como candidato a compor uma vacina contra a malária. No presente estudo geramos cinco proteínas recombinantes baseadas em diferentes regiões do ectodomínio de AMA-1 de Plasmodium vivax, o qual compreende os domínios I a III, com intuito de mapear regiões particularmente imunogênicas da proteína. Cada uma das cinco proteínas recombinantes foi expressa em Eschericha coli a partir do vetor pET-28a em fusão com a cauda de histidina e purificadas por cromatografia de afinidade. As diferentes proteínas recombinantes foram comparadas, por ELISA, quanto ao reconhecimento por anticorpos IgM, IgG e subclasses de IgG de 100 indivíduos infectados por P. vivax procedentes de áreas endêmicas do Estado do Pará e 32 indivíduos não infectados que relataram terem sido acometidos de mais de 10 episódios prévios de malária procedentes do município de Terra Nova do Norte (MT). As freqüências de indivíduos que apresentaram anticorpos IgM foram mais baixas e variaram de 4% (DIII) a 36% (DII-III). Por outro lado, as freqüências de indivíduos que apresentaram anticorpos IgG para DI, DII, DIII, DI-II e DII-III foram 13%, 65%, 12%, 59% e 58%, respectivamente. Podemos observar que as proteínas recombinantes contendo o DII foram particularmente imunogênicas durante a infecção natural. Com o objetivo de avaliar se os epítopos reconhecidos nas cinco proteínas baseadas nos diferentes domínios estão expostos na proteína recombinante correspondente ao ectodomínio (DI-III) gerada previamente, realizamos ensaios de inibição por ELISA utilizando placas sensibilizadas com a proteína DI-III. Nossos resultados sugerem a presença de um maior número de epítopos comuns entre as proteínas recombinantes baseadas nos domínios I-II e ectodomínio de AMA-1. Além disso, observamos que a proporção de indivíduos que apresentaram anticorpos contra DII, DI-II e DII-III aumentou de acordo com o maior número de exposições prévias ao P. vivax. As subclasses de IgG que predominaram contra todas as proteínas foram IgG1, IgG3 e IgG4. Em conjunto, nossos resultados sugerem que as proteínas recombinantes contendo o DII podem ser exploradas em futuros estudos de indução de imunidade protetora contra malária vivax em primatas não-humanos. / The Apical Membrane Antigen 1 (AMA-1) of Plasmodium sp has been suggested as a vaccine candidate against malaria. Herein, to identify novel antigenic epitopes on the Plasmodium vivax AMA-1 ectodomain, we have generated five recombinant proteins, comprising domains I to III. All recombinant proteins were expressed in Escherichia coli using the pET-28a vector system fused to hexahistidine tag for purification by affinity chromatography. Recognition of recombinant proteins by antibodies was evaluated using a panel of sera collected from onehundred P. vivax -infected patients resident in the State of Pará and from thirty-two non-infected individuals, living in the State of Mato Grosso and who have faced a minimum of ten malaria episodes. ELISA analyses demonstrated that protein recognition was highly dependent on IgG antibodies, raging from 13%, 65%, 12%, 59% up to 58%, respectively for DI, DII, DIII, DI-II and DII-III domains. Indeed, we have noticed a lower frequency of recognition, ranging from 4% (DIII) to 36% (DII-III), by sera from those individuals that presented IgM antibodies. Collectively, these data suggest that the DII domain is particularly immunogenic during natural infections. Next, to verify whether the epitopes recognized in these five different recombinant proteins were also expressed in a recombinant protein spanning domains I through III (DI-III), we carried out ELISA inhibition assays using plates coated with the DI-III recombinant protein. Our findings revealed the presence of a higher number of common epitopes among recombinant proteins based on domains I-II and the AMA-1 ectodomain. Moreover, we observed that the proportion of individuals who had presented antibodies against DII, DI-II and DII-III domains increased according to the previous number of P. vivax episodes. Overall, IgG1, IgG3 and IgG4 antibodies were prevalent to all proteins. Taken together, our results demonstrated that DII domain is highly recognized, mainly by IgG antibodies; and open promising perspectives to use this region as an experimental vaccine in non-human primates capable to induce protective immunity against vivax malaria.

Atualmente, o Brasil encontra-se na privilegiada posição de maior produtor e exportador mundial de carne bovina, tornando a pecuária uma das atividades nacionais mais importantes e rentáveis. Este dado enfatiza a importância de pesquisa e desenvolvimento em reprodução bovina, especialmente em hormônios estimuladores da ovulação, tais como a gonadotrofina coriônica equina (eCG). Os produtos comerciais à base de eCG comercialmente disponíveis são purificados a partir do sangue de éguas gestantes, apresentando variabilidade de lote para lote e presença de contaminantes. Estes fatos, juntamente com a limitação do material de partida (sangue equino), enfatizam a necessidade de haver um sistema de expressão de eCG recombinante passível de ser explorado comercialmente. Neste quesito, as células de mamíferos se mostram um sistema robusto para tal finalidade, visto que são capazes de adicionar modificações pós-traducionais às cadeias polipeptídicas, tais como a glicosilação, o que é essencial para o correto dobramento, maturação e montagem das duas subunidades, além de interferir diretamente com a meia-vida, o reconhecimento do receptor, a solubilidade e a atividade biológica das proteínas. No entanto, mesmo entre os sistemas de expressão heteróloga em células de mamífero, encontra-se muita variabilidade nos padrões de glicosilação adicionado. No presente trabalho, foi realizado um estudo comparativo através da clonagem e expressão de uma forma fusionada de eCG (reCGβα) em duas linhagens celulares diferentes: (1) CHO-DG44, um dos sistemas de expressão mais utilizados pelas indústrias farmacêuticas, capaz de adicionar N-glicanos complexos; e (2) 293T, uma linhagem humana capaz de produzir glicoproteínas carreando oligossacarídeos complexos e sialilados. Os resultados de atividade biológica (in vitro e in vivo) apontam uma maior atividade de reCG produzido por células CHO-DG44. O perfil de N-glicosilação de reCG produzido pelas células CHOD-G44 assemelhou-se mais à eCG selvagem, quando comparado a reCG produzido por células 293T. Por fim, estudos clínicos foram realizados com reCG produzido em meio livre de soro fetal bovino e parcialmente purificado, onde atividade específica de reCG produzido por células CHO-DG44 mostrou-se similar ao produto comercial selvagem. / Brazil is currently the major beef producer and exporter, rendering to livestock one of the country´s most economically relevant activities. This emphasizes the importance of research and development in bovine reproduction, especially at ovulation-stimulatory hormones, such as equine gonadotropin (eCG). The commercially available eCG-based products are purified from blood of pregnant heifers, presenting batch-to-batch variability and the presence of contaminants. These facts, together with the limitation of the bulk material (equine blood), emphasize the need of an eCG expression system able to be commercially explored. In this aspect, mammalian cells are a robust system, capable of add post-translational modifications to polypeptide chains, such as glycosylation, which is essential for the correct folding, maturation and assembly of both eCG subunits. In addition, glycosylation directly interferes with the protein half-life, receptor recognition, solubility and biological activity. In the present work, a comparative study was carried out by cloning and expressing a fusion form of eCG (reCGβα) in two different mammalian cell lines: (1) CHO-DG44, one of the most used by pharmaceutical companies expression systems, capable of add complex-type N-glycans; and (2) 293T, a human cell line capable of produce glycoproteins carrying complex and sialylated oligosaccharides. The in vitro and in vivo biological activity results show a higher potency of reCG produced by CHO-DG44 cells. The N-glycosylation pattern produced by CHO-DG44 cells was more similar to native eCG in comparison to the N-glycosylation produced by 293T cells. Finally, clinical studies were performed with serum absent media produced and partially purified reCG, showing that the specific activity of reCG produced by CHO cells was similar to the commercial wild type product.

Deficiência na enzima lisossomal glucocerebrosidase (GCR) resulta na doença de Gaucher. O tratamento atual consiste na administração da enzima exógena, produzida em células CHO. Porém, o medicamento disponível no mercado é extremamente custoso. Neste trabalho, propusemos a clonagem e a expressão da GCR humana em células CHO, visando a obtenção de um clone celular produtor para viabilizar a produção futura da enzima, a um custo menor, no Instituto Butantan. A expressão estável da GCR recombinante foi obtida a partir da transfecção de células CHO-dhfr- com o plasmídeo pED de expressão em células de mamíferos contendo o cDNA da GCR, seguido de amplificação gênica por MTX. A GCR foi detectada no extrato celular (~ 64 kDa) e secretada para o sobrenadante (63-69 kDa) em ensaios de western blotting, usando o anticorpo policlonal anti-GCR gerado neste trabalho. A enzima secretada hidrolisou o substrato 4-MUG e a sua produtividade foi estimada em 5,14 pg/célula/dia para o melhor subclone produtor, selecionado para a produção futura da GCR em larga escala. / Deficiency of the lysosomal glucocerebrosidase (GCR) enzyme results in Gaucher\'s disease. Current treatment consists on enzyme replacement therapy by the administration of recombinant GCR produced in CHO cells. However, the medicine available in the market is extremely expensive. In this work, we proposed the cloning and expression of human GCR in CHO cells, in order to obtain a productive cellular clone for future production of GCR enzyme at a lower cost at the Butantan Institute. The stable expression of recombinant GCR was obtained after transfection of CHO-dhfr- cells with pED mammalian expression vector containing the GCR cDNA, followed by gene amplification with MTX. The GCR was detected by western blotting analysis, either as cell-associated (~ 64 kDa) or as secreted forms (63-69 kDa), using the anti-GCR polyclonal antibody produced in this work. The secreted enzyme was active on 4-MUG and was produced at a level of about 5,14 pg/cell/day for the best producer subclone, selected for subsequent steps of GCR production on large scale in next future.